Keywords: Coronary syndrome drug market, Generic erosion, Integrilin, Aggrastat, Lovenix, Brilinta, anticoagulants
Generic erosion will bite into the acute coronary syndrome market, cutting sales nearly 10% from 2008 to 2018
Article | 08 December 2009
Generic erosion of premium-priced branded agents will offset sales of new agents and will cause the acute coronary syndrome market ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
